The "21st Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering.

This report includes data-rich analysis to help improve your decision making in biomanufacturing. In-depth analysis of capacity, production trends, benchmarks, and more!

This report is a comprehensive analysis of trends and opportunities, biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production. Case studies summarize and highlight specific issues affecting the industry, with an overview of the situation, and a discussion summary.

The report offers:

• In-depth analysis: 500+ pages of data-rich analysis to enhance decision-making in biomanufacturing operations
• Industry trends: Insights from 220 biopharma respondents and 179 suppliers, representing 23 countries
• Subject matter experts: Additional external analysis on trends and future growth
• Capacity and production trends
• Budget Trends and economic impact
• Downstream purification and industry bottlenecks
• Capacity utilization and production levels
• Outsourcing trends and international offshoring
• Disposables and single-use systems
• Batch failure rates and quality management
• Hiring and employment growth
• Supplier growth rates and more

Key Highlights

• 200+ Biopharma company responses
• 170+ industry vendors and suppliers
• 23 Countries represented
• 500+ Pages
• 12 Chapters
• 200+ Graphs and 20+ Tables
• Subject Matter Expert analysis
• Independent Sponsoring Organizations

Key Topics Covered:

Chapter 1: Introduction and Discussion

• 1-1 Sector and Market Overview
• 1-2 Biopharmaceutical Industry Status and Market Trends
• 1-3 Pharma Industry is Shifting to Biopharmaceuticals
• 1-4 Global Biopharmaceutical Market Trends
• 1-5 Biopharmaceutical Markets by Product Class
• 1-6 Future Trends in the Biopharmaceutical Industry

Chapter 2: Future of Bioprocessing: Experts' Perspective

• 2-1 2023 FDA Biopharmaceutical Approvals: Promising Year for Novel Biologics Driven by Innovation and Targeted Therapies
• 2-2 China's Position in Global BioManufacturing: A Comparison of China's Emerging Position vs Established Regions' Manufacturing Capacity and Production
• 2-3 Gene-modified Cell Therapies: A Brief Overview of the Field's Most Advanced Modality
• 2-4 Design Principles and Solutions to Purification Challenges of Asymmetric Fc-Containing Bispecific Antibodies
• 2-5 CRISPR-based Treatment: Capabilities and Challenges

Chapter 3: Trends and Emerging Technologies

• 3-1 Industry Trends in 2024
• 3-2 Bioprocessing Improvements Needed in 2024
• 3-3 Operational Changes in 2024
• 3-4 Budget Issues in 2024
• 3-5 Top Bioprocessing Budget Expenditures
• 3-6 New Bioprocessing Products Development Opportunities (2024)
• 3-7 Cost-Cutting Actions & Development Timelines
• 3-8 Average Cost per Gram Recombinant Protein
• 3-9 Assay Development
• 3-10 Selecting and Purchasing Commercial-Scale Bioreactors
• 3-11 Discussion: Industry Trends and Issues

Chapter 4: Capacity Utilization

• 4-1 Capacity Utilization Trends
• 4-2 Capacity Utilization: Biomanufacturers vs. CMOs
• 4-3 Capacity Utilization: U.S. vs. Western European Manufacturers
• 4-4 Respondents' Current Total Production Capacity
• 4-5 Global Bioreactor Capacity
• 4-6 Range of Titers with mAb Production
• 4-7 Discussion: Capacity and Industry Trends

Chapter 5: Current and Future Capacity Constraints and Quality Factors

• 5-1 Current Capacity Constraints
• 5-2 Expected Capacity Constraints
• 5-3 Factors Impacting Future Production Capacity
• 5-4 Key Areas to Address to Avoid Future Capacity Constraints
• 5-5 Batch Failures in Biopharmaceutical Manufacturing
• 5-6 Automation Implementation
• 5-7 Quality Problems in Biomanufacturing Attributed to Vendors
• 5-8 Discussion: Industry Trends

Chapter 6: Planned Future Capacity Expansions

• 6-1 Planned Future Capacity Expansions
• 6-2 Planned Future Capacity Expansions for Biomanufacturers vs CMOs, by System
• 6-3 Planned Future Capacity Expansions for U.S. vs. Western Europe, by System
• 6-4 Planned Future Capacity Expansions of >100%, by Systems
• 6-5 Planned Future Global Capacity Expansions

Chapter 7: Outsourcing Trends in Biopharmaceutical Manufacturing

• Why Outsource?
• Strategic Manufacturing Planning
• Future Projections
• 7-1 Current Outsourcing by Production System
• 7-2 Future Outsourcing
• 7-3 Outsourced Activities in Biopharmaceutical Manufacturing
• 7-4 CMOs' Problems with Their Clients
• 7-5 Country Selections for International Outsourcing (Offshoring) of Biomanufacturing
• 7-6 Offshoring Trends to Lower-Cost Regions
• 7-7 Discussion of Outsourcing and Offshoring

Chapter 8: Disposables and Single-Use Systems in Biopharmaceutical Manufacturing

• 8-1 Use of Disposables and Single-Use Systems
• 8-2 Leachables and Extractables
• 8-3 Reasons for Increasing Use of Disposables & Single-Use Systems
• 8-4 Factors That May Restrict Use of Disposables
• 8-5 Single-Use Adoption Issues
• 8-6 Need for Single-use Sensors, and Bioreactor Attributes
• 8-7 Satisfaction with Single-Use Device Vendors (2008-2024)
• 8-8 Single-Use Operations and Trends
• 8-9 Discussion: Single-use Bioprocessing

Chapter 9: Downstream Purification

• 9-1 Impact of Downstream Processing on Capacity
• 9-2 Specific Purification Step Constraints
• 9-3 Downstream Purification Issues
• 9-4 mAb Purification Capacity Estimates
• 9-5 New Downstream Processing Technologies
• 9-6 Improvements to Downstream Operations
• 9-7 Discussion: Industry Trends

Chapter 10: Hiring, Employment Growth, and Training in Biopharmaceutical Manufacturing

• 10-1 Hiring Trends
• 10-2 Five Year Trends in Hiring (2029)
• 10-3 Hiring Challenges Today
• 10-4 Training in Biopharmaceutical Manufacturing
• 10-5 Discussion: Strategies For Successful Employment Growth

Chapter 11: New Methods: Continuous and Process Intensification, Cell and Gene Therapies

• Introduction to Innovative Bioprocessing
• Advanced Therapies
• Improved, Continuous Bioprocessing
• 11-1 Future Adoption of Continuous Bioprocessing and Process Intensification
• 11-2 Perfusion Operations and Continuous Bioprocessing Operational Issues
• 11-3 Cell and Gene Therapy Platforms
• 11-4 Discussion

Chapter 12: Suppliers to Biopharmaceutical Manufacturing and Life Sciences

• 12-1 Demographics
• 12-2 Growth Rate of Sales by Suppliers
• 12-3 Budget Issues and Problems Faced by Industry Suppliers
• 12-4 Problems Clients Have with Their Vendors
• 12-5 Impacts of COVID-19 on Suppliers' Activities
• 12-6 Vendors' Products and Services
• 12-7 Sales Staff Training
• 12-8 Biopharma Vendors' Financial Outlook for 2024
• 12-9 CMO Pricing Changes for Biopharmaceutical Services
• 12-10 Discussion: Biopharma Suppliers

For more information about this report visit https://www.researchandmarkets.com/r/2ffdyc

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709416287/en/